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INTRODUCTION
Since the first successful resection for gastric cancer by The-
odor Billroth at Vienna General Hospital in 1881,1 the treat-
ment of gastric cancer has changed and advanced tremen-
dously.2,3 The Department of Surgery, Severance Hospital, 
Yonsei University College of Medicine, has been at the center 
of these changes. This institution is one of the largest centers 
in the world specializing in gastric cancer treatment, and sur-
geons at the hospital perform surgeries on high-risk pa-
tients.4,5 The most recent practices include new techniques, 
such as laparoscopic and robotic surgery.6-10 Not necessarily 
limited to patient care delivery, the surgeons at this institution 
have been leading translational research in the field of gastric 
cancer,11-17 with the advantage of a high volume of surgical 
cases (over 1200 gastrectomies annually). 
Dr. Sung Hoon Noh is a distinguished gastric cancer sur-
geon and a surgical oncologist. He is the head of the Gastric 
Cancer Clinic team at Severance Hospital, and his valuable 
contributions to the field of gastric cancer are important and 
meaningful. As a clinician, he performed his 10000th gastrec-
tomy for gastric cancer on November 7th, 2017. As an aca-
demic surgeon, he has published more than 350 scientific pa-
pers. As a mentor, he has overseen the training of numerous 
international and domestic surgical fellows and residents, and 
has dedicated his career to bettering the understanding of 
gastric cancer and surgical oncology. He has also served in 
various positions in academic societies as a key opinion leader 
in the community. This article reviews his profound contribu-
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tions and long history of service in the field of gastric cancer, 
including his 10000 consecutive gastric cancer surgeries, and 
provides perspectives from his experience. As his contribu-
tions to the field of gastric cancer are extensive, this review will 
surely omit achievements of Dr. Sung Hoon Noh that some of 
his colleagues consider very important. We wish the readers 
will be generous on any omissions. 
 
RÉSUMÉ OF DR. NOH
Dr. Sung Hoon Noh has worked at Severance Hospital since 
1987. He was the 16th Chairman of the Department of Surgery, 
Yonsei University College of Medicine (2009–2013), and Direc-
tor of the Yonsei Cancer Center (2008–2009, 2013–2019). He 
has been a Fellow of the American College of Surgeons since 
2008. He has served as the President of the Korean Gastric Can-
cer Association (2009–2011) and International Gastric Cancer 
Association (2011–2013); the Vice President of the Korean So-
ciety of Gastroenterology (2011–2012), the Chairman of the 
Board of the Korean Cancer Association (2011–2013), and the 
Chairman of the Board (2014–2018); and President of the Ko-
rean Surgical Society (2018–2019). He is a member of the Na-
tional Academy of Medicine of Korea and the Korean Acade-
my of Science Technology. 
REVIEW OF THE 10000 GASTRECTOMIES 
FOR GASTRIC CANCER  PERFORMED 
BY DR. NOH
Dr. Noh performed his first gastrectomy for gastric cancer in 
1987, and has performed 10000 gastrectomies for gastric can-
cer as of November 7, 2017: his annual number of gastrecto-
mies was over 600 at his peak (Fig. 1). The mean age of his pa-
tients was 56.9-years, with 6607 and 3393 male and female 
patients, respectively. He performed 6978 distal subtotal gas-
trectomies and 3022 total gastrectomies, including comple-
tion total gastrectomy. He treated all stages of gastric cancer, 
of which 50.1, 17.3, 27.8, and 4.5% were pathologic stages I, II, 
Fig. 1. Annual number of gastrectomy cases performed by Dr. Noh. STG, subtotal gastrectomy; TG, total gastrectomy including completion total gastrec-
tomy.
Table 1. Summary of 10000 Gastrectomies Dr. Noh Performed
                Variables Number (%) / Mean±SD
Age (yr) 56.9±11.8
Sex, n (%)
Male 6607 (66.1)
Female 3393 (33.9)
Extent of gastrectomy, n (%)
STG 6978 (69.8)
TG 3022 (30.2)
Size (mm) 43.5±30.2
Number of harvested LNs 42.3±15.9
Hospital stays (days) 11.5±8.3
Operation time (min)* 190.1±44.8
Stage, n (%)
I 5012 (50.1) 
II 1725 (17.3) 
III 2777 (27.8) 
IV 446 (4.5) 
NOS 40 (0.4) 
Mortality, n (%)
30 days 31 (0.31)
60 days† 69 (0.69)
STG, subtotal gastrectomy; TG, total gastrectomy including completion total 
gastrectomy; LN, lymph node; NOS, not otherwise specified.
*Including time for anesthesia, †Including 30 days mortality.
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III, and IV, respectively (Table 1). His mean operative time was 
190.1 minutes, including time for anesthesia; the mean hospi-
tal stay was 11.5 days; and there were 31 cases (0.31%) of sur-
gical mortality within 30 days. 
DEVELOPMENT AND 
STANDARDIZATION OF SURGICAL 
TECHNIQUES FOR GASTRIC CANCER 
Dr. Noh first used an electrocautery device, “Bovie” for lymph 
node dissection in gastric cancer surgery in 1989. His use of 
the Bovie device for procedures in gastric cancer surgery in-
creased over time, and he ultimately used the Bovie through-
out the entire procedure. He first presented an operative video 
of gastric cancer surgery using the Bovie in 1995 at the Con-
gress of the Korean Surgical Society. As this technique is now 
common, most young surgeons may not recognize the impor-
tance of this challenge; moreover, many senior surgeons criti-
cized his use of the Bovie due to concerns for thermal injury 
to the bowel and blood vessels. He persevered and advanced 
this procedure and presented another operative video in 1996 
on radical gastrectomy with D2 lymph node dissection for ad-
vanced gastric cancer using the Bovie at the Congress of the 
International Association of Surgeons, Gastroenterologists, 
and Oncologists. This procedure subsequently attracted inter-
national attention among surgeons. 
Next, he expanded the application of the Bovie to spleen-
preserving total gastrectomy. Historically, pancreatico-sple-
nectomy was a standard procedure in radical total gastrectomy 
for gastric cancer because the extent of lymph node dissection 
includes supra-pancreatic and splenic hilar areas. In 1979, Dr. 
Maruyama developed pancreas preserving total gastrectomy. 
In 1995, he reported that pancreas-preserving total gastrecto-
my, compared to conventional total gastrectomy with distal 
pancreatectomy, had low morbidity and mortality with simi-
lar oncologic outcomes, and total gastrectomy with splenec-
tomy subsequently became a standard procedure.18 Dr. Noh 
questioned the necessity of splenectomy for total gastrectomy 
and introduced spleen-preserving total gastrectomy with D2 
lymph node dissection (including splenic hilar lymph node 
dissection). He presented a video of this procedure using the 
Bovie in 1997 at the 2nd International Gastric Cancer Con-
gress.19,20 Because this procedure was considered technically 
very difficult, its feasibility impressed other surgeons, many of 
whom, including gastric cancer experts, came to Yonsei Uni-
versity to observe Dr. Noh’s technique. His clinical data showed 
that spleen preservation during total gastrectomy is associat-
ed with low morbidity and similar or better survival outcomes 
compared to those of total gastrectomy with splenectomy.21,22 
Subsequent studies including a randomized controlled trial 
supported his results,23,24 and spleen preservation is now a 
standard procedure for total gastrectomy. He also developed 
new surgical techniques that can reduce anastomosis leakage 
after gastroduodenostomy.25,26
Dr. Noh has sought to improve survival in gastric cancer 
with peritoneal metastases. He first used cyto-reductive sur-
gery with intraperitoneal chemotherapy for gastric cancer in 
Korea in 1993,27-29 followed by hyperthermic intraperitoneal 
chemotherapy (HIPEC) in 1995. These intraperitoneal treat-
ments for recurrent gastric cancer have been revisited as che-
motherapy regimens have evolved, and HIPEC, extensive peri-
toneal lavage,30 and most recently, pressurized intraperitoneal 
aerosol chemotherapy31 have been attempted and evaluated 
for efficacy in gastric cancer. 
He has always emphasized the importance of oncologic 
principles in gastric cancer surgery to his fellows and residents. 
The “no-touch technique,” in which the tumor is wrapped 
with surgical tape or towels to prevent contamination of the 
surgeon’s hands and dissemination in the surgical field and 
patient’s abdomen, is a key principle in gastric cancer surgery. 
Minimizing manipulation of the stomach to reduce dissemi-
nation of tumor cells through blood and lymphatic vessels, 
anatomical and meticulous dissection with careful hemosta-
sis to prevent direct spillage of tumor cells, and en-bloc lymph-
adenectomy with complete surgical resection of macro/mi-
croscopic tumors (R0) are also basic and important principles 
in gastric cancer surgery. 
PROCEDURAL CHANGES BASED ON 
PATIENT-ORIENTED INSIGHTS
Dr. Noh was interested in reducing discomfort in patients un-
dergoing surgery for gastric cancer. Believing that the patient 
is the most important part of the medical team, he was deeply 
concerned for frequent complaints of postoperative pain from 
the incision, nasogastric tube, and drainage tube. To relieve 
pain, he introduced the epidural patient-controlled analgesia 
pump in the clinic in 1997. He also demonstrated the feasibil-
ity of gastric cancer surgery with a <15-cm midline incision to 
reduce postoperative pain. In addition, to minimize surgical 
stress, he reduced operative time and blood loss, as well as the 
need for transfusion through his use of the Bovie. 
Nasogastric tube insertion was for a long time a standard 
procedure for most gastrointestinal surgeries, with the belief 
that it could reduce postoperative anastomosis leakage and 
decompress bowel gas. He questioned this belief and conduct-
ed a single-center randomized controlled trial to compare 
clinical outcomes with and without nasogastric tube insertion 
for gastric cancer surgery and found no difference between 
the procedures.32 Accordingly, he discontinued routine naso-
gastric tube use for gastric cancer surgery in his clinic. To 
achieve a good operative field during surgery, he developed a 
simple technique to decompress the stomach and colon with-
out the use of a nasogastric tube.33,34
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Dr. Noh also evaluated the necessity of routine intraperito-
neal drainage for gastric cancer surgery and found no differ-
ence in short-term outcomes with or without use of a drain-
age tube.35 As his experience without using a drainage tube 
accumulated, he found that postoperative external drainage is 
required for some patients. He therefore developed a predic-
tive model to identify high-risk patients who would require 
postoperative drainage,36 enabling selective insertion of a drain-
age tube in gastric cancer surgery. His collective efforts were 
the basis for the concept of enhanced recovery after surgery.
IMPROVING SURVIVAL IN GASTRIC 
CANCER THROUGH A MULTIDISCI-
PLINARY APPROACH
After a trial comparing the clinical outcomes of D2 versus D2 
+ para-aortic lymph node dissection failed to show the benefit 
of D4 lymph node dissection,37 the optimal extent of radical 
lymph node dissection was considered D2 level.38-40 As tech-
niques became standardized and postoperative management 
evolved, the benefit of radical surgery to survival in gastric 
cancer had reached a maximum. To improve survival in gas-
tric cancer, another strategy, such as chemotherapy or radia-
tion therapy, was needed; however, until 2001, it was thought 
that surgery was the only effective treatment option for resect-
able gastric cancer.41 The success of the Intergroup and MAG-
IC trials42,43 showed the benefit of perioperative chemotherapy 
and postoperative chemotherapy combined with radiation 
therapy compared to surgery alone, leading to the era of adju-
vant/neoadjuvant therapy for resectable gastric cancer. How-
ever, the trials were criticized because radical surgery with D2 
lymph node dissection was only performed in some of the pa-
tients; furthermore, the prognosis of those who received addi-
tional treatment plus surgery was much worse than in pa-
tients who received radical surgery alone in Korea. 
To evaluate the benefit of adjuvant chemotherapy after rad-
ical D2 surgery for gastric cancer, Dr. Noh and Dr. Yung-Jue 
Bang designed and conducted the Capecitabine and Oxalipl-
atin Adjuvant Study in Stomach Cancer (CLASSIC) trial tar-
geting stage II/III gastric cancer. Thirty-seven institutions from 
Korea, China, and Taiwan participated in this open-label, par-
allel-group, phase III, prospective randomized controlled tri-
al. This trial succeeded in showing the clear survival benefit of 
adjuvant chemotherapy after D2 surgery, compared to D2 
surgery alone.44,45 This result changed clinical practice from a 
D2 surgery alone strategy to D2 surgery plus adjuvant chemo-
therapy and contributed to improvement in survival in gastric 
cancer. These results were included in international guide-
lines for treatment of gastric cancer.40,46,47 
Another phase III, open-label, randomized controlled trial, 
PRODIGY, has been designed by Dr. Noh and Dr. Yoon-Koo 
Kang to determine whether early administration of chemo-
therapy in addition to conventional adjuvant chemotherapy 
would improve survival in gastric cancer (NCT01515748). In 
this study, the effect of Neoadjuvant Docetaxel+Oxaliplatin+ 
S-1 (DOS)+Surgery+adjuvant S-1 compared to Surgery+adjuvant 
S-1 in patients with resectable advanced gastric cancer has 
been investigated. Enrollment in this trial has been completed 
and the final results will be announced soon. The trial is ex-
pected to provide another treatment option for patients with 
gastric cancer. 
INTRODUCTION OF PRECISION 
MEDICINE FOR TREATMENT OF 
GASTRIC CANCER
Despite the success of the CLASSIC trial, there remains a 
number of unmet clinical needs in the treatment of gastric 
cancer. Most of all, few clinically applicable biomarkers have 
been identified for use in stratifying patients with resectable 
gastric cancer according to prognosis and/or response to che-
motherapy. Given that more than approximately 60% of pa-
tients do not seem to benefit from adjuvant chemotherapy af-
ter curative intent D2 surgery, development of clinically 
usable biomarkers to identify these subgroup of patients is an 
urgent need in real-world clinic. According to the final result 
of the CLASSIC trial, estimated 5-year disease-free survival 
was 68% and 53% in the D2 surgery plus adjuvant chemother-
apy group and D2 surgery only group, respectively.44,45 The 
15% added benefit was clinically valuable and suggested that 
half of patients with stage II/III gastric cancer can be treated 
with D2 surgery alone; however, only 15% of those treated 
with adjuvant chemotherapy received real benefit from che-
motherapy, which caused treatment-related toxicity. If we can 
predict who will be cured with surgery alone without use of 
adjuvant chemotherapy, a significant number of patients can 
avoid unnecessary medication-induced toxicity. Moreover, if 
we can predict who will benefit from adjuvant chemotherapy, 
we can select patients for treatment using a current standard 
regimen or a regimen other than standard chemotherapy. In 
the middle of the CLASSIC trial, Dr. Noh realized the need for 
a biomarker study. 
One possible biomarker is microsatellite instability (MSI). 
The clinical characteristics of MSI-high (MSI-H) colorectal 
cancer have been well studied; MSI-H tumors show good 
prognosis and are not responsive to 5-fluorouracil-based che-
motherapy.48 Consequently, guidelines recommend consid-
eration of MSI status in colorectal cancer in deciding whether 
to use adjuvant chemotherapy.49 Dr. Noh and his colleagues 
conducted a meta-analysis and retrospective cohort studies 
to evaluate the clinical implications of MSI-H status in gastric 
cancer. As in colorectal cancer, MSI-H gastric cancer has a 
good prognosis, although the benefit from adjuvant chemo-
therapy in stage II/III gastric cancer was not clear.11,50,51 These 
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results were validated in randomized controlled trial cohorts 
in the CLASSIC and MAGIC studies.12,52,53 Accordingly, MSI 
status has been deemed a powerful candidate biomarker that 
can be used in clinical practice, and treatment guidelines are 
likely to recommend its use in deciding treatment with or 
without chemotherapy for stage II/III gastric cancer. 
Some trials have classified various tumors according to mo-
lecular characteristics,54,55 some of which can be applied in 
clinical practice to predict responsiveness to chemothera-
py.56,57 Some molecular subtypes of gastric cancer have been 
evaluated according to genetic characteristics, including 
mRNA expression levels58-60; however, the clinical implications 
were not clear or validated. Dr. Noh and his colleagues con-
ducted a meta-analysis on mRNA expression data using mul-
tiple gastric cancer cohorts, including those from the Yonsei 
cohort, and found that gastric cancer can be stratified into five 
molecular subtypes based on the expression patterns of tu-
mor transcriptome. Through rigorous statistical analyses, they 
identified four genes (with mRNA expression of five house-
keeping genes), based on a single patient classifier (SPC) al-
gorithm. According to the SPC algorithm, an immune type 
with enriched immune signatures (GZMB- and WARS-posi-
tive) was associated with a good prognosis, but was not re-
sponsive to adjuvant chemotherapy. Cancers with high ex-
pression of cancer stem-cell (ST type)-related gene (SFRP4) 
were associated with the worst prognosis. If cancer exhibits 
high expression of epithelial cell-related gene (CDX1, EP 
type), the benefit from adjuvant chemotherapy is obvious; 
however, a tumor with low expression of CDX1 is likely to re-
ceive no additional benefit from chemotherapy, compared to 
surgery alone. These results were validated in the CLASSIC 
trial cohort;14 consequently, the SPC algorithm was imple-
mented in clinical practice to stratify patients with gastric can-
cer according to whether or not adjuvant chemotherapy should 
Fig. 2. Changes in overall survival for patients with gastric cancer treated at Yonsei Gastric Cancer Center according to stage (AJCC 7th) and time. AJCC, 
American Joint Committee on Cancer.
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
0               20               40               60               80             100
0               20               40               60               80             100
0               20               40               60               80             100
0               20               40               60               80             100
1987–1995
1996–2000
2001–2005
2006–2010
1987–1995
1996–2000
2001–2005
2006–2010
1987–1995
1996–2000
2001–2005
2006–2010
1987–1995
1996–2000
2001–2005
2006–2010
Time after operation (months)
Time after operation (months)
Time after operation (months)
Time after operation (months)
p=0.542
p<0.001
p=0.009
p=0.001
Stage I
Stage III
Stage II
Stage IV
Ov
er
al
l s
ur
viv
al
 (%
)
Ov
er
al
l s
ur
viv
al
 (%
)
Ov
er
al
l s
ur
viv
al
 (%
)
Ov
er
al
l s
ur
viv
al
 (%
)
240
Perspectives on Gastric Cancer
https://doi.org/10.3349/ymj.2019.60.3.235
be given after surgery. Dr. Noh’s collective efforts and achieve-
ments have ushered in the era of precision medicine for treat-
ment of resectable gastric cancer.61 
OTHER CONTRIBUTIONS 
Dr. Noh planed establishing a clinical database in the Yonsei 
Gastric Cancer Clinic in 1993, and the first version was com-
pleted in 1998. This database made it possible to evaluate and 
respond to many clinical questions concerning gastric cancer, 
with the results leading to changes in treatment. Dr. Noh orga-
nized the Yonsei Gastric Cancer Symposium in 2000; this 
symposium was the first gastric cancer-specific conference in 
Korea, and the first to show live surgery in a symposium. The 
Yonsei Gastric Cancer Symposium has become an annual in-
ternational event and has contributed to the dissemination of 
knowledge about gastric cancer surgery, including technical 
tips, treatment, biology, and translational research. Dr. Noh 
has also performed live surgeries in many countries to pro-
mote the excellence of gastric cancer treatment in Yonsei and 
Korea. Many surgeons from other countries including Japan 
visit Korea to learn about surgery for gastric cancer. To edu-
cate doctors who cannot visit Korea, he has organized live 
web seminars and for internet study. The efforts by Dr. Noh 
have led to progressively improved survival of patients with 
gastric cancer at Yonsei (Fig. 2). 
PERSPECTIVES OF A MASTER SURGEON
Although major practice changes and scientific developments 
have occurred over the last decades, continued innovation is 
necessary to curb the burden of gastric cancer. New screening 
systems targeting high-risk individuals based on genomic 
characteristics should be developed for super-early detection 
of gastric cancer. How we manage the rapid increase in survi-
vors of gastric cancer and the occurrence of a second malig-
nancy should be considered. Since the extent of lymph node 
dissection for advanced gastric cancer is set at D2 level, cur-
rent surgery is somewhat standardized rather than personal-
ized. Improving our knowledge of cancer biology will enable 
us to predict lymph node metastasis before surgery, and ad-
vances in technology for intraoperative visualization of lymph 
nodes6 will make it possible to perform tailored surgery. Con-
sequently, the roles of limited and minimally invasive surgery 
including endoscopic resection and robot-assisted surgery 
will expand. Combined targeted therapy and immunotherapy 
based on molecular characteristics if individual tumors will 
be accepted, and the treatment of patients can be tailored in 
greater detail as the concept of the N-of-one trial being real-
ized, leading to personalized treatment. Although surgery has 
not seemed helpful in patients with distant metastases,62 we 
will be able to identify subgroups in which surgery can cure 
the disease, as some of these patients will demonstrate long-
term survival.63 Future changes will be based on not only the 
molecular characteristics of tumor itself but also those of the 
patients, and the importance of a multi-disciplinary approach 
will be further emphasized. Clinician-based Multi-Disciplin-
ary Treatment will and should evolve to Integrative Multi-Dis-
ciplinary Health Care that includes not only clinicians but also 
basic scientists, ancillary providers, and even patients and 
their families. At the center of these changes, surgeons should 
spearhead paving the road and taking legitimate leadership. 
This requires understanding of the biology of cancer and ac-
tive involvement in clinical, translational, and basic research. 
We are now in an era of precision health care beyond preci-
sion surgery. 
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